This article considers some of the problems which can block the successful completion of a clinical research project. Many of these problems are related to the diversity of participants and perspectives which is necessarily present within the context of a clinical trial. General problems faced by the research team during the various phases of the clinical trial are discussed. Suggestions are given for structuring and conducting the trial in a way which will maximize the chance for project success.
PressmanJLWildavskyAB: Implementation.Berkeley, University of California Press, 1973, pp 87–104.
2.
KiltieH: Planning a coordinated set of clinical trials, in LevineJ (ed): Coordinating Clinical Trials in Psychopharmacology: Planning, Documentation, and Analysis. DHEW Publication No. (ADM) 79–803. Washington, DC, USGPO, 1979, pp 5–13.
3.
SpilkerB: Practical considerations in planning and conducting clinical trials with investigational or marketed drugsClin Neuropharm1983; 6:325–347.
4.
AmesME: Outcome Uncertain: Science and the Political Process.Washington, DC, Communications Press, Inc., 1978, pp 165–206.
5.
LevineJ: Coordinating clinical trials in psychopharmacology: Planning, documentation, and analysis: An introduction, in LevineJ (ed): Coordinating Clinical Trials in Psychopharmacology: Planning, Documentation and Analysis. DHEW Publication No. (ADM) 79–803. Washington, DC, USGPO, 1979, pp 1–4.
6.
LevineM: Scientific method and the adversary. Am Psychol1974; Sept:666–677.
7.
MontagneM: Issues in the design and conduct of clinical trialsClin Res Pract Drg Reg Affairs1985; 3:23–44.
8.
SmithCG: Past, current, and future safety and efficacy trends in the drug industryReg Tox Pharm1985; 5:241–254.
9.
BuckalewLW: Methodological issues in drug assessment researchDrug Devel Res1985; 5:103–110.
10.
BlackwelderWC: “Proving the null hypothesis” in clinical trialsCont Clin Trials1982; 3:345–353.
11.
DetskyASSackettDL: When was a “negative” clinical trial big enough? How many patients you need depends on what you foundArch Int Med1985; 145:709–712.
12.
MarlinR: Reliability factors in adverse drug reportingMeth Inform Med1981; 20:157–162.
13.
KowittLMarlinRL: A comprehensive on-line collection systemDrug Inf J1984; 18:9–14.
14.
HayesWL: Statistics for Psychologists.New York, Holt, Rinehart and Winston, 1963, pp 323–333; 381–384.
15.
KeppelG: Design and Analysis: A Researcher's Handbook.Englewood Cliffs, NJ, Prentice Hall, 1973, pp 85–103; 133–163.
16.
CohenJ: Statistical Power Analysis for the Behavioral Sciences.New York, Academic Press, 1969, pp 357–373.
17.
PattonMQ: Utilization Focused Evaluation.Beverly Hills, CA, Sage Publications, 1978, pp 275–291.
18.
ScheinEH: Process Consultation: Its Role in Organizational Development.Reading, MA, Addison-Wesley Publishing Co., 1969, pp 15–30.
19.
AsaiKTanakaHOkudaT: Decision-making and its goal in a fuzzy environment, in ZadehLAFuK-STanakaKShimuraM (eds): Fuzzy Sets and their Applications to Cognitive and Decision Processes.New York, Academic Press, 1975, pp 257–277.
20.
SpilkerB: Guide to Clinical Studies and Developing Protocols.New York, Raven Press, 1984, pp 191–193.
